Share Price | Stevanato Group SpA Stock Analysis & Recommendation

Q: What does Stevanato Group SpA do?

Overview: Stevanato Group SpA operates in the Pharmaceuticals & Biotechnology industry and is classified as a mid-cap company.Financial Snapshot: Most recent Net Sales: 270 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 28 Million (Quarterly Results - Mar 2025) Market-cap: USD 6,576.86 Million (Mid Cap)Key Metrics: P/E: 47.00 Dividend Yield: 0.00% Debt Equity: 0.21 Return on Equity: 9.05% Price to Book: 4.30Contact Details: Registrar Address: Not available.

Q: Is Stevanato Group SpA overvalued or undervalued?

As of 30 June 2025, the valuation grade for Stevanato Group SpA moved from expensive to attractive, indicating a shift towards being undervalued. The company is currently assessed as attractive, with a P/E ratio of 47, a Price to Book Value of 4.24, and an EV to EBITDA of 26.56. In comparison, peers such as TransMedics Group, Inc. have a P/E of 50.23 and an EV to EBITDA of 37.01, while LeMaitre Vascular, Inc. shows a P/E of 49.77 and an EV to EBITDA of 33.90, suggesting that Stevanato Group may offer better value relative to its peers.The stock has performed well against the S&P 500, with a year-to-date return of 25.06% compared to the S&P 500's 12.22%, and a one-year return of 38.04% versus 17.14% for the index, reinforcing the attractiveness of the stock. Overall, Stevanato Group SpA appears to be undervalued based on its current valuation metrics and strong recent performance.

Q: Is Stevanato Group SpA technically bullish or bearish?

As of 31 October 2025, the technical trend for Stevanato Group SpA has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating mixed signals. The daily moving averages are mildly bullish, but the weekly KST is also mildly bearish. Overall, the indicators suggest a cautious bullish stance. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, both down 4.77% compared to the S&P's gains of 0.71% and 1.92%, respectively. However, it has outperformed the S&P 500 year-to-date and over the past year, with returns of 13.54% and 26.29% compared to the S&P's 16.30% and 19.89%.

Results Declared: Stevanato Group SpA has declared results on 04 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

286.26 k

Shareholding (Dec 2025)

FII

21.03%

Held by 71 FIIs

DII

26.17%

Held by 59 DIIs

Promoter

0.00%

How big is Stevanato Group SpA?

22-Jun-2025

As of Jun 18, Stevanato Group SpA has a market capitalization of 6,576.86 million, with net sales of 1,207.41 million and a net profit of 134.59 million for the latest four quarters. The balance sheet shows shareholder's funds of 1,454.19 million and total assets of 2,411.49 million.

View full answer

What does Stevanato Group SpA do?

22-Jun-2025

Stevanato Group SpA is a mid-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $270 million and a net profit of $28 million. Key metrics include a P/E ratio of 47.00 and a market cap of approximately $6.58 billion.

View full answer

Is Stevanato Group SpA overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Stevanato Group SpA is considered attractive and potentially undervalued with a P/E ratio of 47 and strong performance, outperforming the S&P 500, while offering better value compared to peers like TransMedics and LeMaitre Vascular.

View full answer

Is Stevanato Group SpA technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Stevanato Group SpA's trend is mildly bullish with mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

View full answer

Compare Stevanato Group SpA with Similar Stocks

Establishment Labs Holdings, Inc.LeMaitre Vascular, Inc.Myriad Genetics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 14.35%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.73 times

Healthy long term growth as Net Sales has grown by an annual rate of 25.12% and Operating profit at 96.36%

The company has declared Negative results for the last 5 consecutive quarters

With ROE of 9.05%, it has a attractive valuation with a 4.24 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4,191 Million (Small Cap)

P/E

28.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.23

Return on Equity

8.76%

Price to Book

2.48

Revenue and Profits:

Net Sales:

403 Million

(Quarterly Results - Dec 2025)

Net Profit:

55 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.82%

6 Months

-42.81%

1 Year

-25.17%

2 Years

-48.63%

3 Years

-33.45%

4 Years

-10.98%

5 Years

0.0%

Stevanato Group SpA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

21.49%

EBIT Growth (5y)

42.89%

EBIT to Interest (avg)

29.21

Debt to EBITDA (avg)

0.73

Net Debt to Equity (avg)

0.21

Sales to Capital Employed (avg)

0.67

Tax Ratio

26.07%

Dividend Payout Ratio

13.11%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

15.22%

ROE (avg)

14.35%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.48

EV to EBIT

22.32

EV to EBITDA

15.37

EV to Capital Employed

2.21

EV to Sales

3.53

PEG Ratio

1.39

Dividend Yield

ROCE (Latest)

9.89%

ROE (Latest)

8.76%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 46 Schemes (51.43%)

Foreign Institutions

Held by 71 Foreign Institutions (21.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 14.38% vs 2.29% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 7.57% vs 5.97% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "403.30",
          "val2": "352.60",
          "chgp": "14.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "106.10",
          "val2": "86.50",
          "chgp": "22.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "3.20",
          "chgp": "-40.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "-4.80",
          "chgp": "41.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "55.40",
          "val2": "51.50",
          "chgp": "7.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "195.70%",
          "val2": "185.80%",
          "chgp": "0.99%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 12.11% vs 1.77% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 23.86% vs -19.11% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,338.80",
          "val2": "1,194.20",
          "chgp": "12.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "315.00",
          "val2": "251.70",
          "chgp": "25.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.30",
          "val2": "7.40",
          "chgp": "-1.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.90",
          "val2": "-7.70",
          "chgp": "254.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "157.80",
          "val2": "127.40",
          "chgp": "23.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "161.70%",
          "val2": "140.10%",
          "chgp": "2.16%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

403.30

352.60

14.38%

Operating Profit (PBDIT) excl Other Income

106.10

86.50

22.66%

Interest

1.90

3.20

-40.62%

Exceptional Items

-2.80

-4.80

41.67%

Consolidate Net Profit

55.40

51.50

7.57%

Operating Profit Margin (Excl OI)

195.70%

185.80%

0.99%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 14.38% vs 2.29% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 7.57% vs 5.97% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,338.80

1,194.20

12.11%

Operating Profit (PBDIT) excl Other Income

315.00

251.70

25.15%

Interest

7.30

7.40

-1.35%

Exceptional Items

11.90

-7.70

254.55%

Consolidate Net Profit

157.80

127.40

23.86%

Operating Profit Margin (Excl OI)

161.70%

140.10%

2.16%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 12.11% vs 1.77% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 23.86% vs -19.11% in Dec 2024

All Annual Results

Company CV

About Stevanato Group SpA

Stevanato Group SpA

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available